Compare Stocks → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BNTCOTCMKTS:ETSTNASDAQ:PHIONASDAQ:XBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$7.35-3.9%$7.29$1.86▼$10.70$68.87M0.7360,774 shs32,955 shsETSTEarth Science Tech$0.20$0.12$0.00▼$0.32$62.00M1.64140,572 shs89,876 shsPHIOPhio Pharmaceuticals$0.78+6.9%$0.73$0.50▼$3.44$3.58M1.4305,976 shs43,570 shsXBIOXenetic Biosciences$4.05+3.8%$4.03$2.87▼$5.97$6.24M2.375,381 shs3,465 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma-3.92%-18.51%-17.88%+38.42%+73.71%ETSTEarth Science Tech0.00%-9.09%+100.00%+135.57%+400.00%PHIOPhio Pharmaceuticals+6.71%+1.83%-4.97%-9.42%-76.68%XBIOXenetic Biosciences+3.91%+3.91%-5.09%-0.91%+27.04%[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTCBenitec Biopharma2.5827 of 5 stars3.55.00.00.03.70.80.0ETSTEarth Science TechN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals3.2384 of 5 stars3.55.00.00.03.30.81.3XBIOXenetic Biosciences1.0043 of 5 stars0.05.00.00.02.90.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma3.00Buy$16.00117.69% UpsideETSTEarth Science TechN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00413.48% UpsideXBIOXenetic BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest PHIO, BNTC, ETST, and XBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/22/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00(Data available from 6/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K860.87N/AN/A$0.12 per share61.25ETSTEarth Science Tech$50K1,239.93N/AN/AN/A∞PHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/AXBIOXenetic Biosciences$2.54M2.46N/AN/A$6.36 per share0.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-175.36%-127.85%9/19/2024 (Estimated)ETSTEarth Science Tech-$370KN/A0.00∞N/A5.77%20.61%11.73%N/APHIOPhio Pharmaceuticals-$10.83M-$3.25N/A0.21N/AN/A-123.19%-98.58%8/8/2024 (Estimated)XBIOXenetic Biosciences-$4.14M-$2.93N/AN/AN/A-182.99%-43.40%-40.03%8/9/2024 (Estimated)Latest PHIO, BNTC, ETST, and XBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024PHIOPhio PharmaceuticalsN/A-$0.47-$0.47-$0.47N/AN/A5/9/2024Q1 2024XBIOXenetic Biosciences-$0.79-$0.78+$0.01-$0.78$0.65 million$0.51 million4/1/2024Q4 2023PHIOPhio PharmaceuticalsN/A-$0.17-$0.17-$0.17N/AN/A3/21/2024Q4 2023XBIOXenetic Biosciences-$0.87-$0.77+$0.10-$0.77$0.68 million$0.67 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec Biopharma0.014.184.18ETSTEarth Science Tech0.100.870.39PHIOPhio PharmaceuticalsN/A5.485.48XBIOXenetic BiosciencesN/A11.7011.70OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%ETSTEarth Science TechN/APHIOPhio Pharmaceuticals57.31%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma4.30%ETSTEarth Science Tech24.90%PHIOPhio Pharmaceuticals0.59%XBIOXenetic Biosciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma169.37 million8.97 millionNo DataETSTEarth Science Tech8309.98 million232.80 millionNot OptionablePHIOPhio Pharmaceuticals84.59 million4.57 millionNot OptionableXBIOXenetic Biosciences41.54 million1.40 millionNot OptionablePHIO, BNTC, ETST, and XBIO HeadlinesRecent News About These CompaniesMay 29, 2024 | americanbankingnews.comShort Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 39.7%May 9, 2024 | zacks.comXenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue EstimatesApril 10, 2024 | investing.comXenetic Biosciences Inc (XBIO)March 24, 2024 | finance.yahoo.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 22, 2024 | baystreet.caXenetic Dips on Full-Year ResultsMarch 22, 2024 | msn.comXenetic Biosciences reports FY resultsMarch 22, 2024 | accesswire.comXenetic Biosciences, Inc. Reports Full Year 2023 Financial ResultsJanuary 18, 2024 | msn.comXenetic to advance DNase programme with UVA partnershipJanuary 4, 2024 | morningstar.comXenetic Biosciences Inc XBIODecember 11, 2023 | benzinga.comXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastNovember 30, 2023 | finance.yahoo.comMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationNovember 10, 2023 | benzinga.comXenetic Biosciences: Q3 Earnings InsightsNovember 10, 2023 | washingtonpost.comMediciNova: Q3 Earnings SnapshotOctober 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceJuly 13, 2023 | msn.comXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?May 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 5, 2023 | morningstar.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 3, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBenitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Earth Science TechOTCMKTS:ETSTEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Xenetic BiosciencesNASDAQ:XBIOXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
